2021
Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.
Tindana P, de Haan F, Mokuolu O, Guissou R, Bolarinwa O, Ouedraogo J, Tou F, Boon W, Moors E, Dondorp A, Dhorda M, Amaratunga C, Cheah P. Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol. Wellcome Open Research 2021, 6: 75. PMID: 34458588, PMCID: PMC8378406, DOI: 10.12688/wellcomeopenres.16065.1.Peer-Reviewed Original ResearchArtemisinin combination therapyCombination therapyQualitative research methodsViews of stakeholdersDepth interviewsPosition issuesMarket-related issuesCommunity membersNational Malaria Control ProgrammeGlobal malaria deathsArtemisinin combination treatmentSoutheast AsiaGroup discussionsNational regulatory authoritiesMalaria control programmesResearch methodsAfricaACT resistanceMalaria deathsMalaria treatmentStudy protocolMalaria prevalenceAntimalarial medicinesCombination treatmentStakeholders
1992
Variation of the parasite density of Plasmodium falciparum in asymptomatic carriers: consequences for malaria chemoresistance studies.
Guiguemde T, Toe A, Sadeler B, Gbary A, Ouedraogo J, Louboutin-Croc J. Variation of the parasite density of Plasmodium falciparum in asymptomatic carriers: consequences for malaria chemoresistance studies. Medecine Tropicale 1992, 52: 313-5. PMID: 1435194.Peer-Reviewed Original ResearchConceptsDay 4Parasite densityDay 0Plasmodium falciparumAsymptomatic peopleAsymptomatic carriersInclusion criteriaMalaria prevalenceStudy 16Drug absorptionPrimary school childrenParasitaemiaBobo-DioulassoNycthemeral variationsFurther studiesSignificant differencesChildrenSchool childrenVivo testsFalciparumNegativationChemosensitivityGreater numberPrevalenceChemoresistance